Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
|Videos|May 24, 2017
The Therapeutic Approach for Malignant Melanoma: Case 2
The Therapeutic Approach for Malignant Melanoma
Advertisement
April 2017
- A 52-year-old female presented to her dermatologist with a pigmented lesion which had recently become darker; she had it removed for cosmetic reasons
- Pathology revealed a melanoma with a depth of 2.3 mm
- Genetic testing;BRAF V600mutation-positive
- LDH, WNL (174 UI/L)
- She underwent wide local excision and sentinel node mapping; staining is positive for melanoma in the right axillary node
- Complete dissection of the right axilla reveals no additional involved nodes
- CT of the chest, abdomen, and pelvis showed multiple masses in both lungs, the largest being 5 mm
- She underwent core-needle biopsy of the largest lung lesion
- Pathology revealed metastatic melanoma
- Mutation testing:BRAF-positive
- The patient is started on dabrafenib 150 mg bid and trametinib 2 mg qd
Advertisement
Related to this article
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5